Heike Wobst
About Heike Wobst
Heike Wobst is a Senior Scientist currently working at Jnana Therapeutics, where she has been since 2019. She has extensive experience in neuroscience and molecular medicine, having held positions at notable institutions such as AstraZeneca and the University of Oxford.
Current Role at Jnana Therapeutics
Heike Wobst serves as a Senior Scientist at Jnana Therapeutics, a position she has held since 2019. In this role, she contributes to the company's mission of developing innovative therapies for diseases with limited treatment options. Her work involves collaborating with a team of dedicated professionals to advance research and development initiatives.
Previous Experience at AstraZeneca
Prior to her current role, Wobst worked at AstraZeneca as a Principal Scientist in Discovery Biology within the Neuroscience IMED division from 2017 to 2019. During her tenure, she focused on advancing drug discovery efforts in neuroscience, contributing her expertise to the development of potential therapeutic solutions.
Educational Background in Neuroscience
Heike Wobst completed her DPhil in Physiology, Anatomy and Genetics at the University of Oxford, specializing in Neuroscience from 2010 to 2014. Her academic background includes a Bachelor of Science in Molecular Biotechnology from Heidelberg University and a Master of Science in Molecular Medicine from Charite Berlin. This extensive education has provided her with a strong foundation in biological sciences.
Research Experience at Renowned Institutions
Wobst has gained significant research experience at various prestigious institutions. She worked as an Undergraduate Researcher at Dr. Fenning BioMed GmbH and the German Cancer Research Center (dkfz) in 2004 and 2007. Additionally, she served as a Research Assistant at the Max Delbrück Center from 2009 to 2010. These roles have contributed to her expertise in biological research.
Passion for Tackling Therapeutic Challenges
Heike Wobst expresses a strong commitment to addressing diseases that currently have few or no therapeutic options. She values collaboration with passionate and creative colleagues, emphasizing her dedication to advancing scientific research and improving patient outcomes through innovative solutions.